$2500 | Single User
$5000 | Site License
$7500 | Global License

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018
[Report Updated: 29-06-2018]

Published by Global Data: 29 Jun 2018 | 220920 | In Stock
Related Topics: Clinical Trials , Renal Cell Carcinoma

Introduction

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 29-06-2018]

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 5

    Report Guidance 6

    GlobalData Clinical Trials Report Coverage 7

    Clinical Trials by Region 8

    Clinical Trials and Average Enrollment by Country 9

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

    Top Five Countries Contributing to Clinical Trials in Europe 12

    Top Countries Contributing to Clinical Trials in North America 13

    Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

    Top Five Countries Contributing to Clinical Trials in Central and South America 15

    Clinical Trials by G7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 16

    Clinical Trials by Phase in G7 Countries 17

    Clinical Trials in G7 Countries by Trial Status 18

    Clinical Trials by E7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 19

    Clinical Trials by Phase in E7 Countries 20

    Clinical Trials in E7 Countries by Trial Status 21

    Clinical Trials by Phase 22

    In Progress Trials by Phase 23

    Clinical Trials by Trial Status 24

    Clinical Trials by End Point Status 25

    Subjects Recruited Over a Period of Time 26

    Clinical Trials by Sponsor Type 27

    Prominent Sponsors 28

    Top Companies Participating in Renal Cell Carcinoma Therapeutics Clinical Trials 29

    Prominent Drugs 30

    Latest Clinical Trials News on Renal Cell Carcinoma 31

    Jun 20, 2018: SillaJen enrols first patient in REN026 trial 31

    Jun 13, 2018: TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer 31

    Jun 12, 2018: Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 31

    Jun 11, 2018: Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations 32

    Jun 03, 2018: Merck's KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study 32

    Jun 03, 2018: Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) Combination Therapy in Four Different Tumor Types 33

    Jun 03, 2018: Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery 35

    Jun 01, 2018: Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study 35

    May 17, 2018: Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting 36

    May 16, 2018: New Data from Merck's Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting 37

    May 08, 2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo (nivolumab) 38

    May 04, 2018: CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia 38

    Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting 39

    Apr 12, 2018: GamaMabs Pharma to Present New Data on Expression of Anti-Müllerian Hormone type II Receptor in Non-gynecological Cancers and on First ADC Candidate Targeting AMHRII 40

    Apr 10, 2018: Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery 40

    Clinical Trial Profile Snapshots 42

    Appendix 979

    Abbreviations 979

    Definitions 979

    Research Methodology 980

    Secondary Research 980

    About GlobalData 981

    Contact Us 981

    Disclaimer 981

    Source 982

List Of Tables
in Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 29-06-2018]

List of Tables

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2018* 8

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11

Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12

Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2018* 13

Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14

Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2018* 19

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2018* 22

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

List Of Figures, Charts and Diagrams
in Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 29-06-2018]

List of Figures

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11

Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12

Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13

Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14

Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2018* 19

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23

Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29

Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

GlobalData Methodology 980

Additional Details

Publisher

Global Data

Publisher Information

Reference

220920 | GDHC5090CTIDB

Number of Pages

982

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Renal Failure Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care Inc. (U.S. Renal Care) is a healthcare service provider that offers in-center...
10 May 2016 by Global Data USD $250 More Info
Market Access Impact: Renal Cell Carcinoma (US)
IntroductionMarket barriers boost net share for 6 major RCC treatments in US. Is your brand one of t...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Market Access Impact: Renal Cell Carcinoma (EU5)
IntroductionMarket barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (US)
IntroductionOpdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?O...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
Introduction4 medical affairs teams working hard to engage oncologists. Which one gets top marks? Eu...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care, Inc. (U.S. Renal Care) is a healthcare service provider that offers in-cente...
17 Mar 2016 by Global Data USD $250 More Info
NPS+ Renal Cell Carcinoma (US)
IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists ma...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
NPS+ Renal Cell Carcinoma (EU5)
IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstVi...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
Renal Cell Carcinoma: KOL Insight
IntroductionWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Ins...
01 Feb 2015 by FirstWord Pharma USD $7,900 More Info

This report is published by Global Data

Download Free Report Summary PDF

Renal Cell Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 29-06-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)